Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.
PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.
Genetic: gene expression analysis
Genetic: protein expression analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: immunologic technique
|Official Title:||Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy|
- Mean scores for VEGFb and pan-VEGF gene expression by IHC [ Designated as safety issue: No ]
- Comparison of outcome of bevacizumab treatment for groups on either side of the median split of VEGFb:pan-VEGF expression ratios [ Designated as safety issue: No ]
- Gene expression as measured by tissue microarrays [ Designated as safety issue: No ]
- Splice form expression as measured by reverse transcriptase-PCR [ Designated as safety issue: No ]
- VEGF165b protein expression as measured by ELISA [ Designated as safety issue: No ]
|Study Start Date:||July 2007|
- Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy.
OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897754
|Study Chair:||David Bates, PhD||Bristol Heart Institute at University of Bristol|